Company intelligence / Profile preview
Rubius Therapeutics
Cambridge, Massachusetts, United Statesstatnews.com ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Phase 1
01
Overview
Rubius Therapeutics announced plans to liquidate and dissolve in February 2023 after a challenging 2022 where they discontinued their lead candidates and cut 75% of staff. Prior to closure, they were developing cellular therapies based on engineered red blood cells for cancer and autoimmune diseases.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Red Cell Therapeutics (RCTs)Cellular therapiesCell conjugation platform
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Pembrolizumab combination trial
Beyond the preview
Go deeper on Rubius Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rubius Therapeutics.